Tags

Type your tag names separated by a space and hit enter

Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials.
Infect Dis (Lond). 2015; 47(11):808-19.ID

Abstract

BACKGROUND

Oseltamivir has been widely used to treat patients with influenza; however, its effects have been debated. Recently, a new meta-analysis on the controversial topic of oseltamivir's effectiveness found that the drug reduces the duration of influenza symptoms and the risk of hospitalization, while increasing the risk of nausea and vomiting. Unfortunately, the analysis did not include articles published in Chinese. Thus, we performed an updated meta-analysis by adding more studies in China.

METHODS

The terms 'oseltamivir,' 'influenza,' and 'effect' were used to search for publications in both English and Chinese. Only controlled clinical trials were included. We used the weighted mean difference (WMD) or relative risk (RR), together with the 95% confidence interval (95% CI), to estimate the effects of oseltamivir.

RESULTS

A total of 12 studies including 107 712 patients were eligible for analysis. Oseltamivir significantly reduced the duration of fever (WMD, -20.48; 95% CI, -28.43, -12.53) and influenza-like symptoms (WMD, -19.39; 95% CI, -32.94, -5.84). The rates of hospitalization (RR, 0.79; 95% CI, 0.68, 0.90), antibiotics usage (RR, 0.56; 95% CI, 0.42, 0.74), otitis media (RR, 0.78; 95% CI, 0.65, 0.93), and nonspecific complications (RR, 0.58; 95% CI, 0.35, 0.95) were significantly decreased among patients taking oseltamivir. No significant difference was observed with respect to the risk of adverse reactions.

CONCLUSION

Oseltamivir can effectively alleviate the symptoms of influenza and reduce hospitalization, antibiotic usage, and the risk of otitis media without significantly increasing the rate of adverse drug reactions.

Authors+Show Affiliations

From the Department of Epidemiology, School of Public Health, Nanjing Medical University , Nanjing , China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26173991

Citation

Qiu, Sangsang, et al. "Effectiveness and Safety of Oseltamivir for Treating Influenza: an Updated Meta-analysis of Clinical Trials." Infectious Diseases (London, England), vol. 47, no. 11, 2015, pp. 808-19.
Qiu S, Shen Y, Pan H, et al. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infect Dis (Lond). 2015;47(11):808-19.
Qiu, S., Shen, Y., Pan, H., Wang, J., & Zhang, Q. (2015). Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infectious Diseases (London, England), 47(11), 808-19. https://doi.org/10.3109/23744235.2015.1067369
Qiu S, et al. Effectiveness and Safety of Oseltamivir for Treating Influenza: an Updated Meta-analysis of Clinical Trials. Infect Dis (Lond). 2015;47(11):808-19. PubMed PMID: 26173991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. AU - Qiu,Sangsang, AU - Shen,Ye, AU - Pan,Hongqiu, AU - Wang,Jianming, AU - Zhang,Qun, Y1 - 2015/07/15/ PY - 2015/7/16/entrez PY - 2015/7/16/pubmed PY - 2016/3/11/medline KW - Oseltamivir KW - influenza KW - meta-analysis KW - treatment SP - 808 EP - 19 JF - Infectious diseases (London, England) JO - Infect Dis (Lond) VL - 47 IS - 11 N2 - BACKGROUND: Oseltamivir has been widely used to treat patients with influenza; however, its effects have been debated. Recently, a new meta-analysis on the controversial topic of oseltamivir's effectiveness found that the drug reduces the duration of influenza symptoms and the risk of hospitalization, while increasing the risk of nausea and vomiting. Unfortunately, the analysis did not include articles published in Chinese. Thus, we performed an updated meta-analysis by adding more studies in China. METHODS: The terms 'oseltamivir,' 'influenza,' and 'effect' were used to search for publications in both English and Chinese. Only controlled clinical trials were included. We used the weighted mean difference (WMD) or relative risk (RR), together with the 95% confidence interval (95% CI), to estimate the effects of oseltamivir. RESULTS: A total of 12 studies including 107 712 patients were eligible for analysis. Oseltamivir significantly reduced the duration of fever (WMD, -20.48; 95% CI, -28.43, -12.53) and influenza-like symptoms (WMD, -19.39; 95% CI, -32.94, -5.84). The rates of hospitalization (RR, 0.79; 95% CI, 0.68, 0.90), antibiotics usage (RR, 0.56; 95% CI, 0.42, 0.74), otitis media (RR, 0.78; 95% CI, 0.65, 0.93), and nonspecific complications (RR, 0.58; 95% CI, 0.35, 0.95) were significantly decreased among patients taking oseltamivir. No significant difference was observed with respect to the risk of adverse reactions. CONCLUSION: Oseltamivir can effectively alleviate the symptoms of influenza and reduce hospitalization, antibiotic usage, and the risk of otitis media without significantly increasing the rate of adverse drug reactions. SN - 2374-4243 UR - https://www.unboundmedicine.com/medline/citation/26173991/Effectiveness_and_safety_of_oseltamivir_for_treating_influenza:_an_updated_meta_analysis_of_clinical_trials_ DB - PRIME DP - Unbound Medicine ER -